PLRX earnings analysis
What we found in PLRX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Pliant remains an early-stage biotechnology company with no disclosed revenue, gross margin, operating margin or current-quarter EPS in the supplied filing text. Although quarterly and six-month net losses improved to $22.4 million and $42.4 million from $43.3 million and $99.5 million in the comparable 2025 periods, the company reported an accumulated deficit of $901.8 million and expects to require additional capital for clinical development. Liquidity was $159.6 million as of June 30, 2026, which management expects to support operations for the next 12 months and beyond, but the newly emphasized WuXi/BIOSECURE supply-chain exposure adds execution risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $159.6M Cash Runway
- Cash, cash equivalents, restricted cash and short-term investments totaled $159.6 million as of June 30, 2026. Management expects this balance to fund anticipated operating expenses and capital expenditures for the next 12 months and beyond.
- Losses Improved Year Over Year
- Net loss was $22.4 million for the three months ended June 30, 2026, compared with $43.3 million in the prior-year quarter; six-month net loss was $42.4 million versus $99.5 million in the prior-year period.
- Effective Disclosure Controls
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, with no changes in internal controls during the quarter that materially affected or were reasonably likely to materially affect financial reporting.
- Limited Investment Rate Exposure
- The investment portfolio totaled $159.6 million and consisted of bank deposits, money market funds and short-term securities; management states that an immediate 100-basis-point interest-rate change would not materially affect fair value.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- WuXi/BIOSECURE Supply-Chain Risk
- The filing states that WuXi was added to the Department of Defense's Section 1260H list in June 2026 and is expected to be included on the OMB's initial biotechnology companies of concern list due no later than December 2026. A required supplier transition could involve significant cost, operational complexity and delays, although a 5-year grace period may apply.
- Ongoing Losses and Financing Need
- The company reported a $22.4 million quarterly net loss, a $42.4 million six-month net loss and an accumulated deficit of $901.8 million as of June 30, 2026. Management says additional capital will be required to complete clinical development of PLN-101095 and other programs.
- Capital Access and Dilution Risk
- The filing states that existing resources are expected to fund operations for the next 12 months and beyond, but future capital requirements may vary significantly and additional funding may not be available on acceptable terms or at all. The company also has an at-the-market facility allowing up to $50.0 million of common stock sales under the Leerink Sales Agreement.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the filing. Management states existing cash, cash equivalents and short-term investments are expected to fund anticipated operating expenses and capital expenditures for the next 12 months and beyond, but additional capital will be required to complete clinical development of PLN-101095 and other programs.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 11, 2026
- Pliant Therapeutics reported a significant reduction in net loss for Q1 2026 at $20 million, down from $56.2 million in the same quarter last year, reflecting better cost management particularly in R&D expenses, which…
- 10-K · March 3, 2025
- Pliant Therapeutics (PLRX) is a late‑stage fibrosis-focused biotech whose lead small‑molecule bexotegrast program produced positive Phase 2a INTEGRIS data (320 mg showed durable FVC benefit and at Week 24 reduced FVC…
- 10-Q · August 7, 2024
- Pliant reported no revenue for the quarter (Revenue $—) and a widening net loss of $55,854 thousand (net loss per share $(0.92)) for the three months ended June 30, 2024, versus a net loss of $41,192 thousand ($(0.70)…
- 10-K · February 27, 2024
- Pliant Therapeutics’ 2023 Form 10-K emphasizes clinical progress: positive Phase 2a data for bexotegrast in IPF and PSC (notably the 320 mg IPF cohort) and ongoing Phase 2b BEACON‑IPF (~270 patients). The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PLRX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever